GlobeNewswire: Otonomy, Inc. Contains the last 10 of 219 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T22:03:52ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2022/12/22/2578547/0/en/Otonomy-Announces-Change-in-Stock-Exchange-Listing.html?f=22&fvtc=4&fvtv=23010Otonomy Announces Change in Stock Exchange Listing2022-12-22T12:53:19Z<![CDATA[SAN DIEGO, Dec. 22, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC) today announced that it received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (Nasdaq) indicating that the company’s shares would be suspended from trading on Nasdaq effective at the open of business on December 23, 2022. Following such suspension, the company’s shares will be traded on the OTC Pink Market.]]>https://www.globenewswire.com/news-release/2022/12/19/2576689/0/en/Otonomy-Provides-Corporate-Update.html?f=22&fvtc=4&fvtv=23010Otonomy Provides Corporate Update2022-12-19T21:53:43Z<![CDATA[SAN DIEGO, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC) today announced that the company’s board of directors, after considering strategic options, has approved and adopted a Plan of Liquidation and Dissolution (“Plan of Dissolution”) that would include the distribution of remaining cash to stockholders following an orderly wind down of the company’s operations, including the proceeds from the sale of any pipeline assets. To reduce cost, Otonomy has implemented a reduction in workforce. These updates are discussed below.]]>https://www.globenewswire.com/news-release/2022/11/10/2553806/0/en/Otonomy-Reports-Third-Quarter-2022-Financial-Results-and-Provides-Corporate-Update.html?f=22&fvtc=4&fvtv=23010Otonomy Reports Third Quarter 2022 Financial Results and Provides Corporate Update2022-11-10T21:05:00Z<![CDATA[Evaluation of strategic options to realize value from pipeline is ongoing Evaluation of strategic options to realize value from pipeline is ongoing]]>https://www.globenewswire.com/news-release/2022/10/13/2533736/0/en/Otonomy-Reports-Results-from-Clinical-Evaluation-of-OTO-413-Higher-Doses-in-Patients-with-Hearing-Loss.html?f=22&fvtc=4&fvtv=23010Otonomy Reports Results from Clinical Evaluation of OTO-413 Higher Doses in Patients with Hearing Loss2022-10-13T11:30:00Z<![CDATA[SAN DIEGO, Oct. 13, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that the clinical evaluation of higher doses for OTO-413 (0.75 mg and 1.50 mg) in patients with hearing loss demonstrated no clinically meaningful improvement for patients from baseline across multiple speech-in-noise (SIN) hearing tests. These results are in contrast to the positive clinical signal observed with 0.3 mg OTO-413 versus placebo in the previous Phase 1/2 and Phase 2a trial cohorts using the same study design and endpoints.]]>https://www.globenewswire.com/news-release/2022/08/01/2489302/0/en/Otonomy-Reports-Results-from-Phase-2-Clinical-Trial-of-OTO-313-in-Patients-with-Tinnitus.html?f=22&fvtc=4&fvtv=23010Otonomy Reports Results from Phase 2 Clinical Trial of OTO-313 in Patients with Tinnitus2022-08-01T11:30:00Z<![CDATA[SAN DIEGO, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that the OTO-313 Phase 2 trial in tinnitus demonstrated no clinically meaningful benefit versus placebo for primary and secondary endpoints across all timepoints.]]>https://www.globenewswire.com/news-release/2022/07/25/2485387/0/en/Otonomy-Reports-Second-Quarter-2022-Financial-Results-and-Provides-Corporate-Update.html?f=22&fvtc=4&fvtv=23010Otonomy Reports Second Quarter 2022 Financial Results and Provides Corporate Update2022-07-25T20:05:00Z<![CDATA[Conference call and webcast today at 4:30 p.m. ET]]>https://www.globenewswire.com/news-release/2022/07/18/2480960/0/en/Otonomy-to-Report-Second-Quarter-2022-Financial-Results-and-Provide-Corporate-Update.html?f=22&fvtc=4&fvtv=23010Otonomy to Report Second Quarter 2022 Financial Results and Provide Corporate Update2022-07-18T11:30:00Z<![CDATA[SAN DIEGO, July 18, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will report financial results for the second quarter 2022 and provide a corporate update at 4:30 p.m. ET on July 25, 2022.]]>https://www.globenewswire.com/news-release/2022/05/18/2445887/0/en/Otonomy-to-Participate-in-the-H-C-Wainwright-Global-Investment-Conference.html?f=22&fvtc=4&fvtv=23010Otonomy to Participate in the H.C. Wainwright Global Investment Conference2022-05-18T11:30:00Z<![CDATA[SAN DIEGO, May 18, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced its participation in the H.C. Wainwright Global Investment Conference (Hybrid Conference). A pre-recorded company presentation by the Otonomy management team will be available on the conference website beginning at 7 a.m. ET / 4 a.m. PT on May 24, 2022.]]>https://www.globenewswire.com/news-release/2022/05/12/2441834/0/en/Otonomy-Announces-OTO-825-Presentation-at-the-American-Society-of-Gene-Cell-Therapy-Annual-Meeting.html?f=22&fvtc=4&fvtv=23010Otonomy Announces OTO-825 Presentation at the American Society of Gene & Cell Therapy Annual Meeting2022-05-12T11:30:00Z<![CDATA[SAN DIEGO, May 12, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the presentation of preclinical data for OTO-825 at the upcoming American Society of Gene & Cell Therapy (ASGCT) Meeting being held May 16-19 in Washington, DC.]]>https://www.globenewswire.com/news-release/2022/05/09/2439029/0/en/Otonomy-Reports-First-Quarter-2022-Financial-Results-and-Provides-Corporate-Update.html?f=22&fvtc=4&fvtv=23010Otonomy Reports First Quarter 2022 Financial Results and Provides Corporate Update2022-05-09T20:04:00Z<![CDATA[Conference call and webcast today at 4:30 p.m. ET]]>